Seprase (FAP)-Targeted Radioligand Therapy Development
Seprase (FAP)-targeted radioligand therapy (RLT) is at the forefront of cancer treatment innovation. By harnessing the high expression of seprase (FAP) on cancer-associated fibroblasts, these therapeutic agents are able to achieve precise tumor ablation, and with a deep understanding of the unique challenges in this field, Alfa Cytology offers a comprehensive one-stop-shop for the development of seprase (FAP)-targeted RLT to help advance the research and development of cutting-edge therapeutic options.
Introduction to Seprase (FAP)-Targeted Radioligand Therapy
Radioligand therapy (RLT) provides a new therapeutic approach that merges the specificity of molecular targeting agents with the cytotoxic effects of ionizing radiation. In seprase (FAP)-targeted radioligand therapy (RLT), a radionuclide is attached to a molecule that selectively binds to cells expressing seprase (FAP). This allows for selective delivery of therapeutic radiation doses to the tumor site while sparing healthy tissues.
Fig. 1 Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors. (Lindeman, S. D., et al. 2023)
The development of seprase (FAP)-targeted RLT is a milestone toward the much-needed personalized cancer therapy with a promise of better efficacy, and fewer side effects in comparison to existing treatments. With targeting seprase (FAP)'s unique expression pattern in tumors, this approach aims at augmenting patient outcomes across a wide array of solid tumor indications.
Development of Seprase (FAP)-Targeted Radioligand Therapy
The following are theranostic radiopharmaceuticals drug development that target seprase (FAP), including but not limited to:
| Name | Indication | Company | Phase |
|---|---|---|---|
| 225AC-PNT6555 | Solid Tumors | Eli Lilly and Company; POINT Biopharma | Preclinical |
| 177Lu-PNT6555 | Solid Tumors | Eli Lilly and Company; POINT Biopharma | Phase I |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Alfa Cytology offers its expertise in the integrated development of seprase (FAP)-targeted RLT. We are a committed team with state-of-the-art facilities to provide turn-key solutions for any RLT project-from concept to preclinical development. Our seprase (FAP)-targeted RLT development services encompass the following key areas:
Innovative Solutions
In responding to the research and development demands presented by the seprase (FAP)-targeted RDC development, two main service areas have been defined: therapeutically-focused radioligand therapy development and theranostic radiopharmaceuticals development.
Targeting Molecule Design and Optimization
- Small Molecules: Development of high-affinity small molecule ligands for seprase (FAP), optimized for specificity, stability, and pharmacokinetic properties.
- Peptides: Design of peptide-based ligands with more specific binding toward seprase (FAP)-expressing cells.
- Antibodies and Antibody Fragments: Engineering superior targeting capabilities such as monoclonal antibodies single-chain variable fragments (scFvs) or nanobodies.
Radionuclide Selection and Radiochemistry
- Advise on corresponding therapeutic radionuclides based on radiation properties and clinical application.
- Chelator Chemistry: Synthesis of a stable chelator for securely holding a radionuclide, assuring delivery with minimal toxic effects on bystander cells.
- Radiolabeling Optimization: Development of robust radiolabeling protocols to achieve high radiochemical purity and specific activity.
Linker Strategy Development
- Linker Design: Selection and synthesis of suitable linkers that connect the targeting molecule and chelator in a way aimed at stability and in vivo performance.
- Stability Assessment: Assessment of the stability of the linker under physiological conditions that may lead to premature release of the radionuclide.
Building on our comprehensive suite of RLT drug development services, we also specialize in both in vivo and in vitro drug evaluation, ensuring rigorous assessment and validation across all stages of the development process.
At Alfa Cytology, we are specialized to provide full development services for seprase (FAP)-targeted radioligand therapy (RLT). Our team is focused on identification and optimization of the most promising drug candidates to suit your needs. For any further queries on our services or to investigate collaborations, feel free to get in touch with us.
Reference
- Lindeman, S. D., et al. Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2023, 64(5): 759–766.
For research use only.